We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Gets FTC Clearance for Celgene Acquisition
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) announced that the U.S. Federal Trade Commission (FTC) has permitted to close the impending merger with Celgene Corporation after accepting the proposed consent order concerning the same.
The clearance comes after Bristol-Myers agreed to divest Celgene’s psoriasis drug, Otezla.
We remind investors that Celgene entered an agreement with Amgen (AMGN - Free Report) , whereby the latter would acquire the global rights to Otezla for $13.4 billion.
As a result, Bristol-Myers has now satisfied all regulatory requirements under the merger agreement to complete the acquisition of Celgene and expects to close the transaction on Nov 20, 2019.
It also expects the Otezla divestiture to be completed promptly following the closing of the merger.
We note that Bristol-Myers has a tyrosine kinase 2 (TYK2) inhibitor, BMS-986165, in its pipeline, which is being evaluated in several autoimmune diseases, including psoriasis. The regulatory agency was concerned about a possible overlap between Otezla and BMS-986165 in the pipeline. Hence, Bristol-Myers decided to sell Otezla.
Otezla raked in more than $1.4 billion of sales in the first nine months of 2019 and is one of the key growth drivers for Celgene, while BMS-986165 is still in development.
Shares of the company have gained 12.7% in the year so far compared with the industry’s growth of 4.7%.
In January, Bristol-Myers announced that it will acquire Celgene for $74 billion to boost its oncology portfolio, given the stiff competition for Opdivo from the likes of Merck’s (MRK - Free Report) Keytruda. However, the acquisition earlier hit a few roadblocks, with a few large shareholders of Bristol-Myers opposing it. The shareholders thought it to be risky and may add significant debt to the balance sheet. Moreover, Celgene’s growth-driving oncology drug, Revlimid, is expected to lose patent protection soon. The acquisition was finally given a green signal in April.
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Bristol-Myers Gets FTC Clearance for Celgene Acquisition
Bristol-Myers Squibb Company (BMY - Free Report) announced that the U.S. Federal Trade Commission (FTC) has permitted to close the impending merger with Celgene Corporation after accepting the proposed consent order concerning the same.
The clearance comes after Bristol-Myers agreed to divest Celgene’s psoriasis drug, Otezla.
We remind investors that Celgene entered an agreement with Amgen (AMGN - Free Report) , whereby the latter would acquire the global rights to Otezla for $13.4 billion.
As a result, Bristol-Myers has now satisfied all regulatory requirements under the merger agreement to complete the acquisition of Celgene and expects to close the transaction on Nov 20, 2019.
It also expects the Otezla divestiture to be completed promptly following the closing of the merger.
We note that Bristol-Myers has a tyrosine kinase 2 (TYK2) inhibitor, BMS-986165, in its pipeline, which is being evaluated in several autoimmune diseases, including psoriasis. The regulatory agency was concerned about a possible overlap between Otezla and BMS-986165 in the pipeline. Hence, Bristol-Myers decided to sell Otezla.
Otezla raked in more than $1.4 billion of sales in the first nine months of 2019 and is one of the key growth drivers for Celgene, while BMS-986165 is still in development.
Shares of the company have gained 12.7% in the year so far compared with the industry’s growth of 4.7%.
In January, Bristol-Myers announced that it will acquire Celgene for $74 billion to boost its oncology portfolio, given the stiff competition for Opdivo from the likes of Merck’s (MRK - Free Report) Keytruda. However, the acquisition earlier hit a few roadblocks, with a few large shareholders of Bristol-Myers opposing it. The shareholders thought it to be risky and may add significant debt to the balance sheet. Moreover, Celgene’s growth-driving oncology drug, Revlimid, is expected to lose patent protection soon. The acquisition was finally given a green signal in April.
Bristol-Myers currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>